Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -0.75.EBIT: As of FY2025 Q3, the actual value is USD -898.72 K.<h3>Segment Revenue</h3><ul><li>Entero Therapeutics, Inc. did not report any revenue for the three and nine months ended September 30, 2025 and 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, the net loss was $1,152,809, compared to $2,580,971 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $3,410,700, compared to $5,821,067 for the same period in 2024.</li><li>Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $6,673, compared to $206,999 for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $32,080, compared to $882,522 for the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended September 30, 2025, general and administrative expenses were $928,114, compared to $1,685,608 for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $2,362,957, compared to $13,535,241 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $1,729,201, compared to $9,046,305 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $336,427, compared to $88,169 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $3,725,000, compared to $5,613,152 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Assets Held for Sale: As of September 30, 2025, assets held for sale were valued at $83,170,009, with liabilities held for sale at $23,672,708.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Entero Therapeutics plans to continue the development of its Adrulipase program in 2026, focusing on the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients.</li><li>Non-Core Business: The company is seeking to dispose of certain assets and liabilities of its IMGX subsidiary, including Latiglutenase and CypCel, as part of a strategic shift.</li><li>Priority: The company is evaluating all potential strategic options, including a merger, reverse merger, sale, wind-down, liquidation and dissolution or other strategic transaction.</li></ul>

ENTO

Entero Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0